What it is (overview)

Hep C Antibodies – ELISA is a blood test that checks for antibodies to the Hepatitis C virus (HCV). It uses a common laboratory method called ELISA (enzyme-linked immunosorbent assay), which is designed for accurate, large-scale screening.

Antibodies are proteins your immune system makes after exposure to a virus. This test does not look for the virus itself; instead, it looks for evidence that your body has been exposed to HCV at some point.

What the results generally mean:

• Non-reactive / Negative: No Hepatitis C antibodies were detected. This usually means you have not been infected. However, if exposure was very recent, antibodies may not be detectable yet (a “window period”). If there is a strong concern for recent exposure, your clinician may recommend repeat testing and/or an HCV RNA (PCR) test to look for the virus directly.

• Reactive / Positive: Hepatitis C antibodies were detected. This means you have had exposure to HCV at some time. A positive antibody test alone cannot tell whether the infection is current (active) or past (cleared or treated). The next step is usually an HCV RNA (viral load) blood test to confirm whether the virus is still present. If RNA is detected, additional evaluation may include liver enzyme tests (ALT/AST) and assessment for liver inflammation or scarring.

Because Hepatitis C can be silent for years while still causing liver disease, this HCV antibody test is widely used in hepatology and general healthcare as an early detection and screening tool.

When & why it's usually done

Your doctor may order an HCV antibody (ELISA) test for screening, for symptoms that could be related to liver problems, or after potential exposure to blood carrying the virus. Many people with Hepatitis C have few or no symptoms at first, so testing is often based on risk factors.

Common reasons to test include:

• Routine screening: Many guidelines recommend at least one-time screening in adults and periodic screening for people with ongoing risk, because Hepatitis C is a common viral infection that can be treated effectively when found early.

• Symptoms or lab findings suggesting liver involvement: fatigue, nausea, poor appetite, right upper abdominal discomfort, dark urine, pale stools, jaundice (yellowing of skin/eyes), itching, or unexplained elevated liver enzymes (ALT/AST).

• Possible exposure risks: sharing needles or other injection equipment; tattoos or piercings done with non-sterile equipment; needlestick injuries (healthcare); blood or body fluid exposure; or having received certain blood products/transfusions in settings where screening was not assured.

• Medical and personal history factors: people on long-term hemodialysis, those living with HIV, those with a history of incarceration, or those with conditions or treatments that increase exposure risk.

• Pregnancy or pre-treatment evaluation: testing may be done during prenatal care or before starting medications/procedures where knowing infection status helps guide care.

If the antibody test is reactive, confirmatory testing with HCV RNA is important to determine whether you have an active infection that may need treatment and follow-up.

Common diseases related to it

• Hepatitis C virus (HCV) infection (acute or chronic)
• Chronic hepatitis (ongoing liver inflammation)
• Liver fibrosis (scarring) and cirrhosis
• Hepatocellular carcinoma (primary liver cancer) risk related to chronic HCV
• Extrahepatic (outside the liver) complications of chronic HCV (e.g., mixed cryoglobulinemia)
• Coinfections and related risk assessments (e.g., HIV/HCV coinfection)

Health goals where it may help

• Screening for viral infection (Hepatitis C) to support early detection and treatment
• Protecting long-term liver health by identifying risk for liver disease before symptoms develop
• Guiding next-step testing (confirming active infection with HCV RNA and evaluating liver function)
• Preventing transmission by identifying infection status and supporting safer practices
• Supporting hepatology care planning, including treatment eligibility and follow-up goals
• General preventive healthcare screening in at-risk individuals